Undisclosed PRMT5-MTA inhibitor / Schrodinger - LARVOL DELTA

PRMT5-MTA Data at ENA 2024 (Businesswire) - "Additionally, Schrödinger will present new preclinical data on its PRMT5-MTA inhibitor program at a poster session during the meeting on October 25 from 9:00 a.m. - 3:00 p.m. CEST. The presentation (Abstract # 372)...will include preclinical data on the discovery of highly selective PRMT5-MTA inhibitors. The poster will describe how Schrödinger’s virtual screening platform facilitated the identification of structurally distinct chemical matter with a high degree of MTA-synergy for compounds within a novel chemical series in vitro and in cellular contexts."

Preclinical • Oncology • Solid Tumor

Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium (Businesswire) - "Schrödinger...announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and the company’s PRMT5-MTA inhibitor program, will be presented during poster sessions at the 36th EORTC-NCI-AACR Symposium (ENA 2024) taking place October 23-25, 2024 in Barcelona, Spain. The SGR-3515 presentation will include data further characterizing SGR-3515 in preclinical oncology models....Additionally, preclinical data will be presented on the discovery of highly selective PRMT5-MTA inhibitors."

Preclinical • Oncology • Solid Tumor

Schrödinger Reports First Quarter 2024 Financial Results (Businesswire) - "Today, Schrödinger also announced that the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for SGR-3515, its Wee1/Myt1 inhibitor. Schrödinger expects to initiate a Phase 1 dose-escalation trial of SGR-3515 in patients with solid tumors in the third quarter of 2024....Schrödinger is progressing its discovery pipeline, including programs targeting EGFRC797S, PRMT5-MTA and NLRP3. The company continues to anticipate submitting at least one IND in 2025."

IND • New P1 trial • Solid Tumor

Schrödinger Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event (Businesswire) - "Today, Schrödinger outlined the anticipated milestones for its proprietary pipeline: Report initial data from the Phase 1 study of SGR-1505 in late 2024 or 2025; Report initial data from the Phase 1 study of SGR-2921 in late 2024 or 2025; Submit IND for SGR-3515 in the first half of 2024 and initiate a Phase 1 study in 2024; Submit an IND from its discovery portfolio in 2025..."

IND • P1 data • Acute Myelogenous Leukemia • CNS Tumor • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • Solid Tumor

Schrödinger Reports Third Quarter 2023 Financial Results (Businesswire) - "Today Schrödinger announced the initiation of the Phase 1 clinical study of SGR-2921, an investigational CDC7 inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndrome. The study is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and determine the recommended dose....Schrödinger continues to advance SGR-3515, an inhibitor of Wee1 and Myt1....IND-enabling activities are ongoing to support an IND submission for SGR-3515 in the first half of 2024....Today Schrödinger announced that one of its previously undisclosed discovery programs is PRMT5-MTA (protein arginine methyltransferase 5/methylthioadenosine)....The company expects to provide more details about its PRMT5-MTA program and other early-stage programs at its Pipeline Day on December 14, 2023."

IND • Pipeline update • Trial status • Acute Myelogenous Leukemia • Myelodysplastic Syndrome